Insulin Glargine 300U/mL: A Review in Diabetes Mellitus.

Abstract

Insulin glargine 300U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100U/mL (Lantus(®)), with a duration of glucose-lowering activity exceeding 24h. In several 6-month phaseIII trials, insulin glargine 300U/mL achieved comparable glycaemic control to that seen with insulin glargine 100U/mL in patients with type1 or type2 diabetes, albeit with consistently higher daily basal insulin requirements. These improvements in glycaemic control were maintained during longer-term (12months) treatment. Insulin glargine 300U/mL was generally associated with a lower risk of nocturnal hypoglycaemia than insulin glargine 100U/mL in insulin-experienced patients with type2 diabetes, while the risk of nocturnal hypoglycaemia did not significantly differ between treatment groups in insulin-naïve patients with type2 diabetes or in patients with type1 diabetes. To conclude, once-daily subcutaneous insulin glargine 300U/mL is an effective and generally well tolerated basal insulin therapy option for patients with type1 or type2 diabetes.